Any leakage around a percutaneous left atrial appendage (LAA) implant, no matter how small, predicted strokes and other thrombotic events after the procedure, according to a retrospective study. In ...

The FLX Pro’s new polymer layer, dubbed Hemocoat, is designed to promote tissue growth over the implant while tamping down inflammation. (Paul Campbell/Getty Images) Boston Scientific has obtained an ...

Procedural success and safety outcomes in real-world populations with nonvalvular atrial fibrillation (AF) undergoing left atrial appendage occlusion (LAAO) with the Watchman FLX device (Boston ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

On Saturday, Boston Scientific Corporation (NYSE:BSX) unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device ...

Boston Scientific thinks Watchman represents a $500 million market opportunity, but how are physicians viewing the device now that reimbursement is available? Boston Scientific's left atrial appendage ...

Marian Regional Medical Center has successfully completed its 500th Watchman procedure, a milestone in providing advanced treatment options for patients with atrial fibrillation (AFib). The Watchman ...

The Cottage Heart & Vascular Center’s structural heart team at Santa Barbara Cottage Hospital (SBCH) recently performed their 1,000th WATCHMAN device procedure, a minimally invasive solution for ...

When it comes to people with non-valvular atrial fibrillation (AFib), the risk of stroke is five times greater than that of those without it. While your heart valves function correctly, “electrical ...